MX2014013315A - Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. - Google Patents
Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.Info
- Publication number
- MX2014013315A MX2014013315A MX2014013315A MX2014013315A MX2014013315A MX 2014013315 A MX2014013315 A MX 2014013315A MX 2014013315 A MX2014013315 A MX 2014013315A MX 2014013315 A MX2014013315 A MX 2014013315A MX 2014013315 A MX2014013315 A MX 2014013315A
- Authority
- MX
- Mexico
- Prior art keywords
- particles
- showing improved
- improved mucosal
- mucosal transport
- nanoparticles showing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Abstract
Se proporcionan partículas, composiciones, y métodos que ayudan al transporte de partículas en el moco. En algunas modalidades, las composiciones y los métodos pueden incluir modificar los revestimientos de superficie de las partículas, tales como las partículas de los agentes farmacéuticos que tienen una baja solubilidad acuosa. La composición farmacéutica que incluye tales partículas se adecua bien para las aplicaciones oftálmicas, y puede utilizarse para suministrar agentes farmacéuticos a la parte frontal del ojo y/o la parte posterior del ojo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642313P | 2012-05-03 | 2012-05-03 | |
US201261642261P | 2012-05-03 | 2012-05-03 | |
US201261738949P | 2012-12-18 | 2012-12-18 | |
US201361784701P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/039540 WO2013166436A1 (en) | 2012-05-03 | 2013-05-03 | Pharmaceutical nanoparticles showing improved mucosal transport |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014013315A true MX2014013315A (es) | 2015-09-10 |
Family
ID=48464113
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014013315A MX2014013315A (es) | 2012-05-03 | 2013-05-03 | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. |
MX2020007227A MX2020007227A (es) | 2012-05-03 | 2014-11-03 | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007227A MX2020007227A (es) | 2012-05-03 | 2014-11-03 | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. |
Country Status (13)
Country | Link |
---|---|
US (4) | US20130316006A1 (es) |
EP (1) | EP2844223A1 (es) |
JP (3) | JP6720443B2 (es) |
KR (2) | KR102373259B1 (es) |
CN (5) | CN111700880A (es) |
AU (3) | AU2013256092B2 (es) |
BR (1) | BR112014027296B1 (es) |
CA (1) | CA2871748C (es) |
CL (3) | CL2014002956A1 (es) |
HK (2) | HK1208161A1 (es) |
MX (2) | MX2014013315A (es) |
NZ (5) | NZ741873A (es) |
WO (1) | WO2013166436A1 (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
RU2598627C2 (ru) | 2012-01-19 | 2016-09-27 | Дзе Джонс Хопкинс Юниверсити | Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки |
AU2013232300B2 (en) | 2012-03-16 | 2015-12-17 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
CN104363924B (zh) | 2012-03-16 | 2018-04-17 | 约翰霍普金斯大学 | 用于递送hif‑1抑制剂的控制释放调配物 |
WO2013166436A1 (en) * | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
EP4008355A1 (en) * | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP3808339A1 (en) | 2012-05-03 | 2021-04-21 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US10864219B2 (en) * | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
JP2016517435A (ja) | 2013-03-15 | 2016-06-16 | カラ ファーマシューティカルズ インコーポレイテッド | メロペネム誘導体及びその使用 |
RU2015144689A (ru) | 2013-03-21 | 2017-04-25 | ЮПРАКСИЯ ФАРМАСЬЮТИКАЛЗ ЮЭсЭй ЭлЭлСи | Композиция для инъекций с замедленным высвобождением и способ ее применения для лечения воспаления в суставах и связанной с такими воспалениями боли |
EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
CA2913417A1 (en) | 2013-05-30 | 2014-12-11 | Kala Pharmaceuticals, Inc. | Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
AU2015223068B2 (en) | 2014-02-25 | 2020-07-30 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
AU2015252908B2 (en) * | 2014-05-01 | 2017-12-07 | Integral Biosystems Llc | Membrane-adherent self-assembled systems for treatment of ocular disorders |
KR101501217B1 (ko) * | 2014-07-17 | 2015-03-10 | 최명 | 필러용 폴리디옥사논 입자의 제조방법 |
PL3179982T3 (pl) | 2014-07-28 | 2023-09-25 | Sun Pharma Advanced Research Company Ltd | Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku |
EP3193827A1 (en) * | 2014-08-13 | 2017-07-26 | The Johns Hopkins University | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization |
BR112017006918A2 (pt) * | 2014-10-09 | 2017-12-12 | Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L | formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares |
WO2016060921A1 (en) * | 2014-10-15 | 2016-04-21 | Rapid Pathogen Screening, Inc. | Formulations for histatin protectives and therapeutics |
KR102511830B1 (ko) | 2014-11-25 | 2023-03-17 | 엑시모어 엘티디. | 단일 및 다수 생체활성제를 전달하기 위한 조성물 및 방법 |
US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
CA2969467A1 (en) | 2014-12-10 | 2016-06-16 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
WO2016094617A1 (en) * | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
EP3233058A1 (en) | 2014-12-15 | 2017-10-25 | The Johns Hopkins University | Sunitinib formulations and methods for use thereof in treatment of glaucoma |
US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
CA2974715C (en) | 2015-01-27 | 2020-05-05 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
KR101730399B1 (ko) | 2015-04-13 | 2017-04-27 | 영남대학교 산학협력단 | 악시티닙을 포함하는 약물 전달체 및 이의 제조방법 |
KR102643821B1 (ko) | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
TWI664965B (zh) | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
US10729663B1 (en) * | 2015-08-21 | 2020-08-04 | University Of South Florida | Nanoparticles in thermoreversible gels for enhanced therapeutics |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
WO2017035355A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
BR112018005589A2 (pt) | 2015-09-22 | 2018-10-09 | Graybug Vision Inc | “composto, composição farmaceuticamente aceitável, e, uso de um composto” |
US10036135B2 (en) * | 2015-10-23 | 2018-07-31 | Philip S. Dunlap | Methods and systems to contain pollution and hazardous environments (CPHE) |
CN108289857A (zh) | 2015-10-27 | 2018-07-17 | 优普顺药物公司 | 局部***的持续释放制剂 |
AU2016343840A1 (en) * | 2015-10-30 | 2018-06-07 | The Johns Hopkins University | Mucus penetrating particles with high molecular weight and dense coatings |
EA038755B1 (ru) | 2015-11-12 | 2021-10-14 | Грейбаг Вижн, Инк. | Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки |
JP7082115B2 (ja) | 2016-06-02 | 2022-06-07 | エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 |
TWI752083B (zh) | 2016-09-13 | 2022-01-11 | 日商協和麒麟股份有限公司 | 醫藥組合物 |
CA3037176A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
WO2018053318A1 (en) * | 2016-09-16 | 2018-03-22 | Kala Pharmaceuticals, Inc. | Particles, compositions, and methods for ophthalmic and/or other applications |
EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
WO2018175268A1 (en) * | 2017-03-19 | 2018-09-27 | Biohealthways, Inc. | Biodegrading implantable ocular sustained release drug delivery system |
EP3600324A4 (en) | 2017-03-23 | 2020-12-09 | Graybug Vision, Inc. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS |
US20200163900A1 (en) * | 2017-05-08 | 2020-05-28 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
WO2019055028A1 (en) * | 2017-09-15 | 2019-03-21 | Kala Pharmaceuticals, Inc. | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS |
KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
EP3712181B1 (en) | 2017-11-15 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid derivative modified with polyethylene glycol |
JP2021523124A (ja) * | 2018-05-02 | 2021-09-02 | オキュソフト インコーポレイテッドOCuSOFT,Inc. | 次亜塩素酸をベースにした眼瞼洗浄剤 |
EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
AU2019346464A1 (en) | 2018-09-25 | 2021-04-08 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor D inhibitors |
CN110664757B (zh) * | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
WO2020223177A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
EP3999153A4 (en) * | 2019-07-16 | 2023-08-16 | The Regents Of The University Of Michigan | COMPOSITE DRUG PARTICLES AND ASSOCIATED USES |
ES2944558T3 (es) * | 2019-10-01 | 2023-06-22 | Evonik Corp | Proceso de preparación de nanopartículas en forma de polvo que comprenden un poliéster biorreabsorbible |
EP4069220A4 (en) * | 2019-12-04 | 2024-04-24 | Restore Vision Llc | OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA |
CN113214419B (zh) * | 2021-05-06 | 2022-10-25 | 温州医科大学附属眼视光医院 | 一种乳糖酸修饰的聚2-溴乙基丙烯酸酯及其制备方法与应用 |
CN113414049B (zh) * | 2021-06-04 | 2023-04-18 | 圣托马斯先进材料公司 | 一种智能雾化器及其使用方法 |
US20230111190A1 (en) * | 2021-09-14 | 2023-04-13 | Nulixir Inc. | Oral compositions with improved bioavailability and methods of making the same |
WO2023114375A2 (en) * | 2021-12-16 | 2023-06-22 | Alveolus Bio, Inc. | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease |
US20230233375A1 (en) * | 2022-01-24 | 2023-07-27 | Celanese Eva Performance Polymers Llc | Implantable Device for Delivery of a Tyrosine Kinase Inhibitor |
WO2023235794A2 (en) * | 2022-06-01 | 2023-12-07 | The Trustees Of The University Of Pennsylvania | Adhesive particles for active delivery |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5619321B2 (es) * | 1971-09-22 | 1981-05-07 | ||
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
PT996429E (pt) * | 1997-10-27 | 2003-06-30 | Merck Patent Gmbh | Solucoes e dispersoes no estado solido de farmacosfracamente soluveis em agua |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
WO2003103633A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
WO2005030257A2 (en) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles inclusion complexes |
CA2548376A1 (en) * | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
KR101243689B1 (ko) * | 2005-03-09 | 2013-03-14 | 도레이 카부시키가이샤 | 미립자 및 의약품 조성물 |
DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
WO2007076448A2 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
CN101317847B (zh) * | 2007-06-06 | 2010-10-13 | 深圳市瑞谷医药技术有限公司 | 一种眼用或耳鼻用药物组合物及其用途 |
CN101129385B (zh) * | 2007-08-14 | 2010-07-21 | 山东博士伦福瑞达制药有限公司 | 含加替沙星和依碳酸氯替泼诺的眼用组合物及其制备方法 |
US20110065774A1 (en) * | 2008-01-31 | 2011-03-17 | Alnylam Pharmaceuticals | Chemically modified oligonucleotides and uses thereof |
TWI580441B (zh) * | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | 穩定的藥學次微米懸浮液及其形成方法 |
CA2756072A1 (en) * | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
US8889193B2 (en) * | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
US20150056300A1 (en) * | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
US20120121718A1 (en) | 2010-11-05 | 2012-05-17 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2013166436A1 (en) * | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
-
2013
- 2013-05-03 WO PCT/US2013/039540 patent/WO2013166436A1/en active Application Filing
- 2013-05-03 NZ NZ741873A patent/NZ741873A/en not_active IP Right Cessation
- 2013-05-03 BR BR112014027296-4A patent/BR112014027296B1/pt active IP Right Grant
- 2013-05-03 AU AU2013256092A patent/AU2013256092B2/en active Active
- 2013-05-03 NZ NZ742004A patent/NZ742004A/en not_active IP Right Cessation
- 2013-05-03 CN CN202010551342.8A patent/CN111700880A/zh active Pending
- 2013-05-03 NZ NZ728721A patent/NZ728721A/en not_active IP Right Cessation
- 2013-05-03 US US13/886,602 patent/US20130316006A1/en not_active Abandoned
- 2013-05-03 NZ NZ742005A patent/NZ742005A/en not_active IP Right Cessation
- 2013-05-03 KR KR1020217002733A patent/KR102373259B1/ko active IP Right Grant
- 2013-05-03 US US13/886,658 patent/US20130316001A1/en not_active Abandoned
- 2013-05-03 CN CN202010551329.2A patent/CN111700879A/zh active Pending
- 2013-05-03 CN CN202010551315.0A patent/CN111714472A/zh active Pending
- 2013-05-03 JP JP2015510490A patent/JP6720443B2/ja active Active
- 2013-05-03 CN CN201380035493.6A patent/CN104661647A/zh active Pending
- 2013-05-03 EP EP13723629.5A patent/EP2844223A1/en active Pending
- 2013-05-03 MX MX2014013315A patent/MX2014013315A/es active IP Right Grant
- 2013-05-03 NZ NZ700875A patent/NZ700875A/en not_active IP Right Cessation
- 2013-05-03 CA CA2871748A patent/CA2871748C/en active Active
- 2013-05-03 CN CN202010551316.5A patent/CN111700878A/zh active Pending
- 2013-05-03 KR KR1020147033577A patent/KR20150006869A/ko active Application Filing
-
2014
- 2014-10-30 CL CL2014002956A patent/CL2014002956A1/es unknown
- 2014-11-03 MX MX2020007227A patent/MX2020007227A/es unknown
-
2015
- 2015-09-09 HK HK15108779.3A patent/HK1208161A1/xx unknown
- 2015-09-21 HK HK15109260.7A patent/HK1208382A1/xx unknown
-
2018
- 2018-02-20 AU AU2018201215A patent/AU2018201215B2/en active Active
- 2018-05-30 US US15/992,494 patent/US20180271782A1/en not_active Abandoned
-
2019
- 2019-10-03 JP JP2019182856A patent/JP2020015758A/ja active Pending
- 2019-11-25 CL CL2019003432A patent/CL2019003432A1/es unknown
- 2019-11-25 CL CL2019003433A patent/CL2019003433A1/es unknown
-
2020
- 2020-05-08 AU AU2020203052A patent/AU2020203052C1/en active Active
- 2020-07-31 US US16/945,398 patent/US20210052489A1/en active Pending
- 2020-11-20 JP JP2020193338A patent/JP7372897B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020007227A (es) | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. | |
MX2021007794A (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
MX355739B (es) | Composiciones y articulos para el cuidado personal. | |
PH12015502587B1 (en) | Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same | |
MX353036B (es) | Articulos solubles de dosis unitaria que comprenden un polimero cationico. | |
MX362413B (es) | Particula de suministro que contiene agente benefico con base en copolimero de estireno anhidrido maleico. | |
MX340962B (es) | Agentes de enlace a receptor de canabinoide, composiciones y metodos. | |
AU2013334740A8 (en) | Stable, low viscosity antibody formulation | |
MX2015000337A (es) | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. | |
NZ608380A (en) | Pharmaceutical composition comprising deferasirox | |
PH12014502571A1 (en) | Ophthalmic compositions with improved dessication protection and retention | |
MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
MX2016003238A (es) | Composiciones antisepticas cationicas. | |
MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
MX2016015208A (es) | Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen. | |
GB2514741A (en) | Composition for use as a paint binder | |
PH12015502820A1 (en) | Nanoparticulate formulation comprising a trpa1 antagonist | |
MX2018012682A (es) | Conjugados de acido hialuronico y usos de los mismos. | |
MX2022005317A (es) | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. | |
NZ733080A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
IN2014MU00284A (es) | ||
NZ728136A (en) | Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition | |
TR201905694T4 (tr) | Aripiprazol ön ilaç bileşimleri. | |
WO2016008401A8 (zh) | 一种含多西他赛的药物组合物 | |
MX356050B (es) | Composicion farmaceutica acuosa con estabilidad mejorada. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |